A review of classical and novel pharmacological therapies for maintaining sinus rhythm in atrial fibrillation, emphasizing the limitations of current options and the need for targeted drugs.
Current AF rhythm-control options remain limited; leaves open targeted drug development for future trials.
Atrial fibrillation is the most common cardiac arrhythmia and is a major cause of cardiovascular morbidity and mortality in the Western world. Present pharmacological options are limited by inefficacy, proarrhythmia and end-organ toxicity. Enhanced understanding of the underlying causes of this pleotropic entity may allow the creation of targeted drugs that avoid the pitfalls of current options. This review concentrates on both the classical and novel pharmacological therapies aimed at maintaining sinus rhythm.
No takes yet. Share an insight, caveat, or question.
Patton et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: